Literature DB >> 34063871

Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.

Laurits Fredsgaard1, Louise Goksøyr1,2, Susan Thrane2, Kara-Lee Aves1, Thor G Theander1, Adam F Sander1,2.   

Abstract

Capsid virus-like particles (cVLPs) are used as molecular scaffolds to increase the immunogenicity of displayed antigens. Modular platforms have been developed whereby antigens are attached to the surface of pre-assembled cVLPs. However, it remains unknown to what extent the employed cVLP backbone and conjugation system may influence the immune response elicited against the displayed antigen. Here, we performed a head-to-head comparison of antigen-specific IgG responses elicited by modular cVLP-vaccines differing by their employed cVLP backbone or conjugation system, respectively. Covalent antigen conjugation (i.e., employing the SpyTag/SpyCatcher system) resulted in significantly higher antigen-specific IgG titers compared to when using affinity-based conjugation (i.e., using biotin/streptavidin). The cVLP backbone also influenced the antigen-specific IgG response. Specifically, vaccines based on the bacteriophage AP205 cVLP elicited significantly higher antigen-specific IgG compared to corresponding vaccines using the human papillomavirus major capsid protein (HPV L1) cVLP. In addition, the AP205 cVLP platform mediated induction of antigen-specific IgG with a different subclass profile (i.e., higher IgG2a and IgG2b) compared to HPV L1 cVLP. These results demonstrate that the cVLP backbone and conjugation system can individually affect the IgG response elicited against a displayed antigen. These data will aid the understanding and process of tailoring modular cVLP vaccines to achieve improved immune responses.

Entities:  

Keywords:  conjugation system; modular vaccine platform; vaccine; vaccine design; virus-like particle

Year:  2021        PMID: 34063871     DOI: 10.3390/vaccines9060539

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  59 in total

1.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

Review 2.  The influence of virus structure on antibody responses and virus serotype formation.

Authors:  M F Bachmann; R M Zinkernagel
Journal:  Immunol Today       Date:  1996-12

3.  Structure of AP205 Coat Protein Reveals Circular Permutation in ssRNA Bacteriophages.

Authors:  Mihails Shishovs; Janis Rumnieks; Christoph Diebolder; Kristaps Jaudzems; Loren B Andreas; Jan Stanek; Andris Kazaks; Svetlana Kotelovica; Inara Akopjana; Guido Pintacuda; Roman I Koning; Kaspars Tars
Journal:  J Mol Biol       Date:  2016-08-31       Impact factor: 5.469

4.  SnoopLigase Catalyzes Peptide-Peptide Locking and Enables Solid-Phase Conjugate Isolation.

Authors:  Can M Buldun; Jisoo X Jean; Michael R Bedford; Mark Howarth
Journal:  J Am Chem Soc       Date:  2018-02-14       Impact factor: 15.419

5.  Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.

Authors:  Mona O Mohsen; Ariane C Gomes; Gustavo Cabral-Miranda; Caroline C Krueger; Fabiana Ms Leoratti; Jens V Stein; Martin F Bachmann
Journal:  J Control Release       Date:  2017-02-28       Impact factor: 9.776

6.  DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.

Authors:  Uta G Lange; Pietro Mastroeni; Jenefer M Blackwell; Carmel B Stober
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.

Authors:  Robert Schwenk; Margot DeBot; Michael Porter; Jennifer Nikki; Lisa Rein; Roberta Spaccapelo; Andrea Crisanti; Paul D Wightman; Christian F Ockenhouse; Sheetij Dutta
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

8.  Explanations for the high potency of HPV prophylactic vaccines.

Authors:  John Schiller; Doug Lowy
Journal:  Vaccine       Date:  2018-01-08       Impact factor: 3.641

Review 9.  Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.

Authors:  Mark K Slifka; Ian J Amanna
Journal:  Front Immunol       Date:  2019-05-01       Impact factor: 8.786

Review 10.  New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue.

Authors:  Karl D Brune; Mark Howarth
Journal:  Front Immunol       Date:  2018-06-26       Impact factor: 7.561

View more
  1 in total

1.  Comparison of Bacterial Expression Systems Based on Potato Virus Y-like Particles for Vaccine Generation.

Authors:  Anete Ogrina; Dace Skrastina; Ina Balke; Ieva Kalnciema; Juris Jansons; Martin F Bachmann; Andris Zeltins
Journal:  Vaccines (Basel)       Date:  2022-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.